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Abstract
Type 2 diabetes mellitus (DM) is a lifelong metabolic 
disease, characterized by hyperglycaemia which 
gradually leads to the development and progression 
of vascular complications. It is recognized as a global 
burden disease, with substantial consequences on 
human health (fatality) as well as on health-care 
system costs. This review focuses on the topic of his-
torical discovery and understanding the complexity 
of the disease in the field of pathophysiology, as well 
as development of the pharmacotherapy beyond 
insulin. The complex interplay of insulin secretion and 
insulin resistance developed from previously known 
“ominous triumvirate” to “ominous octet” indicate the 
implication of multiple organs in glucose metabolism. 
The pharmacological approach has progressed from 
biguanides to a wide spectrum of medications that 
seem to provide a beneficial effect on the cardiovascular 
system. Despite this, we are still not achieving the 
target treatment goals. Thus, the future should bring 
novel antidiabetic drug classes capable of acting on 
several levels simultaneously. In conclusion, given the 
raising burden of type 2 DM, the best present strategy 
that could contribute the most to the reduction of 
morbidity and mortality should be focused on primary 
prevention.
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Core tip: Type 2 diabetes mellitus (DM) is a global 
burden disease and one of the leading all-cause mortality 
causes due to cardiovascular (CV) complications. The 
rapid raise in the understanding of its pathogenesis 
resulted in treatment approach options beyond insulin 
that also provide beneficial CV effect. We discuss this 
scientific pathological and pharmacological development 
through a comprehensive historical approach. The wide 
spectrum of therapeutic agents currently used in type 2 
DM treatment result in a CV mortality reduction which 
is not exclusively in correlation with glucose-lowering 
potency but is linked to its mechanism of action. 
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INTRODUCTION
Diabetes mellitus (DM) is chronic, lifelong progressive 
metabolic disease characterized by hyperglycaemia 
due to absolute or relative insulinopaenia. There are 
several different types of DM and each are caused by a 
complex interplay between genetic predisposition and 
environmental factors. The metabolic dysregulation 
that contributes to hyperglycaemia includes dimini­
shed insulin secretion, impaired glucose utilization or 
increased glucose production, and eventually causes 
pathophysiological changes in multiple organs and 
organ systems[1]. Despite all the scientific advances 
in the field of pathophysiology, diagnosis and treat­
ment, the prevalence of DM has shown a dramatic rise 
over the past 200 years. Nowadays, DM represents 
a global burden disease with fatal consequences on 
human health, and significant impact on health­care 
system costs. It is estimated that in 2017, there were 
451 million people (ages 18­99 years) with diabetes 
worldwide[2], and this number is expected to rise, 
mostly due to type 2 DM. Thus, we review herein the 
longitudinal history and therapeutic approaches beyond 
insulin for type 2 DM. 
HISTORY AND CLASSIFICATION OF DM 
The first documented symptoms of DM were recorded 
by ancient physicians in 1552 B.C. in a 3rd Dynasty 
Egyptian papyrus, being described as a rare mysterious 
disease characterized by excessive urination which leads 
to emaciation and death[3,4]. Around year 150 of the 
new era, the term “diabetes mellitus” meaning “honey” 
and “siphon” was introduced by an ancient Greek 
physician Aretaeus, reflecting the sweet urine taste in 
affected individuals[5]. However, its recognition as what 
is called a “clinical entity” ­ a condition that has separate 
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and distinct existence from any known underlying cause 
or specific treatment option - occurred in an 1822 pub-
lication in the New England Journal of Medicine and 
Surgery[6].
The idea beyond this disease was not clarified until 
1889, when Josph von Mering and Oskar Minkowski 
found that pancreatomy performed on a dog resulted 
in fatal diabetes[7,8]. In 1910, Edward Albert Sharpey­
Schafer hypothesized that this might be due to the 
lack of a single pancreatic chemical, which he call­
ed “insulin”[6]. His hypothesis was confirmed by the 
discovery of insulin in 1921 by Frederick Banting and 
Charles Best[9,10]. After initially reversing diabetes in a 
dog using an extract from pancreatic islets of a healthy 
dog, together with James Collip and John Macleod they 
purified the hormone from bovine pancreas and used it 
to treat diabetes in humans[11]. 
From that point of time, DM has represented a 
fertile ground for scientific research[12]. Since 1923, 
10 scientists have received a Nobel prize for diabetes­
related investigation[6]. Over the past two centuries 
it became clear that DM does not represent a unique 
clinical condition with a common pathophysiological 
background. Namely, insulin transformed the lives of 
children and young adults with diabetes but had limited 
impact upon the survival of those diagnosed at the age 
of 50[6]. 
The classification of DM is primarily based on the 
pathogenic process that results in hyperglycaemia. 
In brief, it is now well known that severe insulin defi-
ciency accounts for about 10% of all DM cases and 
is characterized by selective autoimmune destruction 
of insulin producing pancreatic β­cells, which are cla­
ssified as type 1 DM, usually occurring in younger, 
lean individuals[1]. The majority of patients, however, 
belong to the group with insulin resistance as the 
core pathophysiological disorder rather than insulin 
deficiency[1], classified as type 2 DM. This type of DM 
is phenotypically often accompanied by central obesity, 
hypertension and dyslipidaemia. 
The different pathophysiological background of 
hyperglycaemia was first proposed by Himsworth[13] in 
the year 1936, who tested the ability of injected insulin 
to clear an oral glucose load from the circulation. He 
concluded that there were insulin sensitive patients 
whose diabetes was due to insulin deficiency and in­
sulin insensitive patients whose diabetes was due to 
resistance to insulin. These findings were strengthened 
by the research of Claude Bernard, who showed that 
blood glucose is also regulated by the non­glucose 
precursors driven by the liver[14­16], which probably re­
present the core of diabetes classification that was, 
however, not adopted until the 1970s[17] under the terms 
“maturity onset diabetes” and “non­insulin­dependent 
diabetes” (NIDDM). Those were abandoned in favour of 
the newer terminology between 1980 and the 1990s. 
The categorization of DM involving two principal groups, 
namely type 1 and type 2 DM, raises its own concerns, 
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especially in terms of type 2 DM because of diversity 
in clinical presentation and the natural course of the 
disease requiring an individual therapeutic approach[18]. 
PATOPHYSIOLOGY OF TYPE 2 DM: 
WHAT HAVE WE LEARNED IN THE LAST 
CENTURY? 
Type 2 DM (formerly known as NIDDM) is a common 
metabolic disorder characterized by insulin resistance, 
relative impairment in insulin secretion, and certain 
degree of genetic predisposition, the prevalence of 
which markedly rises with the degree of obesity[1]. It is 
often accompanied by hypertension and dyslipidaemia: 
high serum low density lipoprotein concentrations and 
low serum high density lipoprotein concentrations that 
increase cardiovascular (CV) risk. The constellation 
of these clinical conditions is referred to as metabolic 
syndrome. Although, the risk factors associated with 
this type of DM were observed as early on as the 1920s 
and the term “metabolic syndrome” was coined in the 
1950s when the French physician Jean Vague noticed 
that upper body obesity seemed to be associated with 
an increased risk for the conditions of atherosclerosis, 
diabetes, kidney stones and gout[19]. He also noticed that 
these patients show significant improvement in their 
diabetes, high blood cholesterol and high triglycerides 
following a low­calorie and low­carbohydrate diet[20]. 
The term became commonly used in the 1970s, and 
in the 1988, Gerald Reaven hypothesized that insulin 
resistance could be the underlying factor linking this 
constellation of abnormalities, which he went on to 
name “syndrome X”[21,22].
Indeed, it is now well known that type 2 DM 
usually presents with varying degrees of insulin re­
sistance, consequent relative insulin deficiency, and 
hyperglycaemia which further impair pancreatic β­cell 
function, resulting in a vicious cycle of metabolic state 
worsening[23]. In addition, it is now well known that the 
majority of type 2 DM patients have genetic risk for 
its development. Its importance is supported primarily 
due to the observation that normoglycaemic offspring 
of type 2 DM parents have reduced non­oxidative 
glucose metabolism associated with increased muscle 
intracellular lipid content and reduced muscle glycogen 
synthesis[1]. This is due to a complex interaction among 
many genes and environmental factors (i.e., a complex 
polygenic interplay which finally results in insulin 
resistance, namely decreased insulin sensitivity) that 
represents a core pathophysiological factor in type 2 DM 
development. 
The exact molecular mechanism leading to insulin 
resistance has not been elucidated so far. Although the 
amount of insulin receptor expression on target tissues 
is diminished due to insulin’s cellular internalization 
and reduced tyrosine kinase activity, the different exp­
ression probably represents the secondary and not the 
primary defect. It is considered that the post­receptor 
alterations in insulin receptor substrate­1 (IRS­1), 
regulating phosphorylation and dephosphorylation, 
might play a predominant role in this condition. Pre­
cisely, there is an imbalance between IRS­1 tyrosine 
and serine phosphorylation (Figure 1)[24]. Diminished 
IRS­1 tyrosine phosphorylation results in reduced 
translocation of glucose transporter type 4 (GLUT­4) 
to the plasma membrane, which enables glucose 
influx into the cells. Simultaneously, enhanced IRS-1 
serine phosphorylation activates mitogen­activated 
proteins, whose action is not involved in metabolic but in 
mitotic insulin activity and proinflammatory pathways 
activation which result in intramitochondrial stress and 
further enhance insulin resistance. It is also implicated 
in the diabetes­related micro­ and macrovascular 
complications’ development. In brief, insulin resistance 
consists of two tightly coupled mechanisms: lack of 
suppression of glucose production and lack of glucose 
uptake by peripheral tissues, primarily muscles. 
Skeletal muscles usually utilize more than 80% of 
the circulating glucose in the presence of circulating 
insulin, while in the condition of insulin resistance this 
effect is diminished[19­22,24,25].
Furthermore, during the overnight fast, there is a 
substantial (1.8­2.0 mg/kg per min) glucose production, 
essential to meet the needs of the brain and other 
neural tissues whose uptake accounts for 50%­60% 
of total glucose disposal and is insulin independent. In 
euglycaemic individuals, the hepatic glucose production 
is suppressed following the glucose influx into the portal 
vein due to rise in insulin and inhibition in glucagon 
release[1]. In type 2 DM, this mechanism is diminished, 
which then results in both fasting as well as postp­
randial hyperglycaemia. The mechanisms involved in 
hepatic glucose production include hyperglucagonaemia, 
increased levels of circulating glucose precursors, free 
fatty acid oxidation, enhanced sensitivity to glucagon 
and decreased sensitivity to insulin[1,24]. 
A gradual increase in insulin resistance requires a 
notable higher amount of insulin in order to overcome 
hyperglycaemia. Consequently, as pancreatic β­cells 
start to release insulin from its secretory granules, a 
higher amount of amylin appears in higher concentration 
in circulation but also in pancreas itself[1,23]. Circulat­
ing amylin decreases glucose uptake in peripheral 
tissues, i.e., enhances insulin resistance, while the 
pancreatic amylin further decreases pancreatic insulin 
secretion contributing to the hyperglycaemic state in 
both cases[1]. Thus, this complex interplay of insulin 
secretion and insulin resistance in the liver and the 
skeletal muscle, also known as “ominous triumvirate”[1], 
represented the first proposed fundamental mechanism 
of type 2 DM development and progression over the 
last two decades, i.e., ever since it was established by 
a prospective study carried out by Jallut et al[26] in 1990 
and later supported by many prospective studies carried 
out in diverse ethnic populations[27,28]. 
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However, since 1990 and until 2009, due to tech­
nological and pharmacological advances, there was 
a growing body of literature suggesting that the “omi­
nous triumvirate” was not the sole pathophysiological 
disturbance in type 2 DM. An exponential growth of 
experimental and clinical studies suggested the po­
ssible implications of other organs: primarily pancreatic 
glucagon producing cells (α­cells), visceral adipose 
tissue, gut, kidneys and central nervous system. This 
was finally defined by DeFronzo[29] in 2009 under the 
term “ominous octet”. As it gradually became evident 
that persons affected by type 2 DM have mostly a 
specific adipose tissue topography, i.e., that visceral 
obesity is often accompanying type 2 DM, the two 
might be considered a part of this pathogenic pro­
cess. It has been shown that they are also insulin 
resistant, resulting in the antilipolytic effect and thus 
leading to daylong elevation in the plasma free­fatty 
acid concentration[30­36], which not only further disrupts 
pancreatic β­cell function[37,38] but also promotes hepatic 
and muscle insulin resistance[39­41] and stimulates 
gluconeogenesis[42,43]. Moreover, the visceral adipocytes 
have a secretory capacity for a number of biological 
active products, including the adipokines, namely 
adiponectin, leptin, resistin, tumour necrosis factor­α, 
interleukine­1β, plasminogen activator inhibitor­1, 
retinol binding protein 4, etc., which are all associated 
with the function of intermediary metabolism[30,44]. 
After the basic elucidation of these so­called “dy­
sharmonius quartet”, at the beginning of the 2000s, 
the concept of type 2 DM pathophysiology was further 
expanded to include the gastrointestinal tissues as 
the fifth member of the “quintessential quintet”. Even 
back in 1932, it was observed that the administration 
of an extract from the upper intestine could produce a 
fall in blood glucose, and the presumed hormone was 
named “incretin”[45]. Moreover, it was noticed that oral 
glucose administration resulted in a much greater insulin 
secretion, as compared to intravenous glucose infusion 
in a concentration that mimicked orally­absorbed plasma 
glucose concentration[46­48]; the phenomena was called 
“incretin effect”. The discovery of two gastrointestinal 
peptides ­ glucose­dependent insulinotrophic peptide 
secreted by the K­cells of the more proximal small 
intestine, and glucagon like peptide­1 (GLP­1) secreted 
by the L­cells of the distal small intestine ­ probably 
mediate > 99% of this “incretin effect”. They have been 
shown to delay gastric emptying, stimulate insulin and 
suppress glucagon secretion in a glucose­dependent 
manner. In fact, the diminished “incretin effect” has 
been repeatedly shown in type 2 DM patients[49­52].
The sixth member of the “octet” is the pancreatic 
α­cell. We have already mentioned glucagon, i.e., the 
lack of glucagon suppression in the context of hepatic 
insulin resistance as well as in the incretion part, so 
it does not come as surprise that the higher fasting 
plasma glucose has been documented in several 
clinical studies in type 2 DM individuals back from the 
1970s[53­58]. It has been demonstrated that higher 
concentrations of fasting glucagon closely correlate with 
Figure 1  The molecular mechanism of insulin resistance. In insulin resistance, the binding of insulin to its receptor does not result in serine phosphorylation 
of insulin receptor substrate-1 and activation of the cascade of intracellular substrates’ activation which result in glucose influx, glucagon and protein synthesis, 
and lipolysis inhibition. IRS: Insulin receptor substrate; Ser/Thr: Serine/threonine protein kinase; Tyr: Tyrosine kinase; PI-3: Phosphatidylinositol 3; PDK-1: 
Phosphoinositide-dependent protein kinase-1; Akt/PBK: AKT serine/threonine kinase 1 (protein kinase B family); PDE: Phosphodiesterase; cAMP: Cyclic adenosine 
monophosphate; PKA: Protein kinase A; GLUT4: Glucose transporter type 4.
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the increase in fasting hepatic glucose production as 
described in detail earlier in the paper. Furthermore, 
the authors showed a simultaneous decrease following 
somatostatin infusion. Thus, it is clear that hyperg­
lucagonemia merits being considered as one of the key 
features in the pathogenesis type 2 DM. 
In addition to muscle, liver, pancreatic α­cell and 
β­cells, adipocytes and the gut, the kidney is one of 
the two most recent members implicated in the path­
ophysiology of type 2 DM. Although excessive urination 
was one of the first described characteristics of DM[3­5] 
and the effort of its reduction was one of the first 
therapeutic approaches to DM while the sweet urine 
taste represented one of the first diagnostic approaches 
for DM, its pivotal role in type 2 DM pathogenesis 
was only recently explained. Physiologically, a total of 
approximately 162 g of glucose is filtered by kidneys 
on daily basis, and 90% of that amount is reabsorbed 
by the high capacity of sodium­glucose­transporter­2 
(SGLT2) in the renal proximal tubule, while the re­
maining 10% of the filtered glucose is reabsorbed by 
the SGLT1 transporter in the descending part of the 
proximal tubule[59]. The result is that no glucose appears 
in the urine in healthy individuals. During the last two 
decades it became evident that in both type 1 and type 
2 DM the maximal renal tubular reabsorptive capacity 
is increased[60,61]. This mechanism is due to markedly 
increased levels of SGLT2 mRNA and protein itself in 
the proximal renal tubular cells in type 2 DM[62]. In 
conclusion, the overactivation of an adaptive response 
by the kidney to conserve glucose seems to play an 
important role in hyperglycaemia development in type 2 
DM. 
Finally, the last component of the “ominous octet” 
is the central nervous system. Following functional 
magnetic resonance imaging investigations, it became 
evident that certain hypothalamic areas, precisely 
those which are involved in appetite regulation, show 
diminished inhibitory response in insulin­resistant type 
2 DM individuals compared to normal glucose tolerant 
subjects, even though the plasma insulin response was 
noted as markedly increased in the obese group. This 
indicates that besides peripheral tissues, the insulin 
resistance, a common feature of all type 2 DM subjects, 
exists is the central nervous system. 
Therefore, it is evident that the last few decades 
provided better and comprehensive knowledge on 
the pathophysiology of type 2 DM, which certainly 
had repercussion on the pharmacological treatment 
approach.
LONGITUDINAL HISTORY OF 
TREATMENT OPTIONS IN TYPE 2 DM 
From the very beginning, even back in the times when 
frequent and excessive urination was considered a 
hallmark of DM, physicians tried to understand how it 
could be managed. They initially used the methods that 
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could decrease this process, and there are documents 
reporting that horseback riding often was one of the 
first proposed methods[5]. Centuries later, Rollo[63] 
established the link between consumed food and 
the amount of glucose in the urine. He observed that 
carbohydrates increased glucose levels, while animal 
products’ consumption resulted in less glucose[3,4,64]. 
Thus, he proposed that DM treatment should be 
based on a high fat and protein rich diet with low 
carbohydrates. This modification of diet became the 
recommended treatment for diabetes until the discovery 
of insulin[65]. 
Since the first proposal in 1877, a series of modi­
fications and even individualized approaches, such 
as “oat­cure”, “potato therapy” and the “starvation 
diet”, persisted until 1916. This was the year when a 
Boston scientist, Elliot Joslin, was established as one 
of the leading diabetes experts upon creating The 
Treatment of Diabetes Mellitus textbook, wherein he 
reported that fasting diet combined with regular but 
moderate physical activity could significantly reduce 
the risk of death in diabetes[66]. Although the diet and 
physical activity concept underwent numerous changes, 
especially over the last two decades, they still represent 
two official fundamental treatment approaches for 
type 2 DM, beyond pharmacological treatment[67], and 
probably will remain so in the future. 
The pharmacological treatment options in type 2 
DM, however, did not occur until after the 1900s, and 
in the century of their development resulted in a wide 
spectrum of insulin and non­insulin hypoglycaemic 
agents experiencing an exponential growth. Although 
the discovery of insulin is considered the beginning 
of the pharmacological “DM­treatment” era, it is less 
known that the discovery and the use of oral hypogly­
caemic agents (OHL) started 60 years ago, with an OHL 
class of biguanides that now represent the basic, first-
line pleiotropic agent known as metformin[67]. Namely, 
during the medieval times, the French lilac plant 
(Galega officinalis) was used to relieve DM symptoms in 
Southern and Eastern Europe[68]. At the beginning of the 
20th century, the anti­hyperglycaemic compound of the 
plant, guanidine, was isolated, synthesized and named 
Synthalin[69]. The further development of Synthalin and 
other guanidine homologs was stopped since they were 
hepatotoxic, and completely ended with the discovery 
and global use of insulin[70]. However, a resurgence of 
interest in the biguanides occurred several decades 
later, as the pathophysiology of DM as well as the 
difference in its clinical presentation (i.e., before­
mentioned classification) became clearer. Although 
metformin was introduced in 1959, its wide clinical use 
started two decades after and it was not approved in 
the United States until 1990[68­71]; meanwhile, other 
agents from this class ­ phenformin and buformin ­ 
resulted in a significant number of lactic acidosis, which 
led to their withdrawal[70]. Nowadays, metformin repre­
sents the only clinically significant biguanide whose 
Blaslov K et al . Comprehensive history of type 2 diabetes
214 December 15, 2018|Volume 9|Issue 12|WJD|https://www.wjgnet.com
increase in the incidence of bladder cancer[79]. However, 
the wide use of rosiglitazone was soon associated 
with an increased risk of myocardial infarction, which 
led to its temporary market restriction, i.e., it remain­
ed available only in the United States. However, in 
November 2013, there was a change in position based 
on the findings of the large “Rosiglitazone Evaluated 
for Cardiovascular Outcomes and Regulation of Gly­
cemia in Diabetes” (RECORD) study, demonstrating 
that individuals treated with rosiglitazone did not have 
an elevated risk of myocardial infarction compared 
to those taking other antihyperglycemic agents[81,82]. 
Despite this, pioglitazone remains the most used TZD 
at the present time, taking its place in all the available 
diabetes management guidelines as the first to second 
option, but one cannot speculate whether rosiglitazone 
will dominate the market in the near future.
Before the endocrine role of gut itself in the “incretin 
effect” became a clear and important pathophysio­
logical player in type 2 DM development (which then 
led to introduction of so called “incretin” group of anti­
hyperglycaemic agents), a class of drugs targeting gut, 
precisely small intestine α­glucosidase and thereby 
decreasing glucose absorption, was introduced into 
clinical practice[74­78]. The first drug in this category 
of α­glucosidase inhibitors that reached the market 
was acarbose, back in 1995, followed a year later 
by miglitol. Despite the logical background of drug 
development, neither drug has ever been used widely, 
probably because of the modest impact on A1C and 
their gastrointestinal side effects. However, following 
the discovery and elucidation of the incretin­insulin 
pathway, the “incretin based” class of agents became 
an intriguing and rapid growing area of research and 
development in the pharmaceutical industry. 
At first, researchers became interested in the 
development of dipeptidyl­peptidase inhibitors ­ ag­
ents that could be taken orally and would prolong 
the circulating half­life of endogenous incretins[45­47,74]. 
First among these was sitagliptin, in 2006[83]; this was 
soon followed by saxagliptin, linagliptin, vildagliptin 
and alogliptin, comprising a separate OHL class, the 
“gliptines”. Obviously, these drugs showed good results 
in the post­market clinical trials, as nowadays they are 
recommended even as second­line diabetes therapy[67]. 
Parallel to those, GLP­1 analogues were developed. The 
first analogue, exenatide was produced from exendin-4, 
which was isolated from the salivary gland venom of the 
Gila monster (Heloderma suspectum)[45­47,74]. This drug 
become available for clinical use in 2005[74]. A second 
GLP­1 receptor agonist, liraglutide, was approved in 
2010. Soon after, i.e., over the last 8 years, the market 
of GLP­1 analogues has grown exponentially, starting 
with the once­weekly form of exenatide, dulaglutide, 
lixisenatide and albiglutide, to lately with semaglu­
tide[74]. Although these drugs major advantage is weight 
loss, they also show cardio­ and neuro­protective 
effects[67,84,85]. However, the exact mechanism of these 
post­market results remains to be elucidated.
primary mechanism of action is the ability to reduce 
hepatic gluconeogenesis and glycogenolysis due to 
enhancement of insulin resistance[72].
The sulfonylureas (SUs) represent the second and 
latest class of OHL, the discovery of which was trigg­
ered by the observation of an accidental hypoglycaemic 
effect. All the other OHL classes developed rapidly 
during the last two to three decades, accompanied 
by a deeper understanding of the complex path­
ophysiology of type 2 DM at the molecular level. The 
history of SUs starts in 1937, with the observation 
of hypoglycaemic activity of the synthetic sulphur 
compounds[73] and which was further confirmed by 
hypoglycaemia occurrence in typhoid patients treated 
with antibiotic para­amino­sulfonamide­isopropyl­
thiodiazole[74]. In 1946, Auguste Loubatieres confirmed 
that aryl SU compounds stimulated release of insulin 
and, therefore, they require the remaining pancreatic 
β­cell function to achieve the effect[73,74]. Soon after, 
in the 1950s, the first SU ­ tolbutamide ­ was mar­
keted in Germany[74], followed by the introduction of 
the other first­generation SU agents­chlorpropamide, 
acetohexamide, and tolazamide. The next advancement 
in SU therapy was the release of the more potent 
second­generation agents, back in 1984 ­ glipizide, 
glyburide, and gliklazide ­ and the third­generation 
agent glimepiride which was released in 1995[73­75]. 
Nowadays, the SUs are widely used, since they are 
generally safe, inexpensive, and relatively predicta­
ble, with hypoglycaemia as the primarily use­limiting 
side effect. In addition, due to research advances in 
seeking an agent that could be used with less fear of 
hypoglycaemia, the class of meglitinides was released 
on the market in 2000[76,77]. The meglitinides act similar 
to SUs, i.e., they enhance insulin secretion but their 
effect is diminished at low glucose concentrations. Thus, 
they might cause hypoglycaemia but less frequently 
and less severe than the “conventional” SUs[74]. 
The class of thiazolidinediones (TZDs) was initially 
introduced to the market in the middle of 1990. As 
a peroxisome proliferator–activated receptor-γ drug 
class activator, they were recognized soon after the 
discovery that the activation of this precise cell surface 
receptor enhances skeletal muscle insulin sensitivity 
and reduces hepatic glucose production[31,78]. This class 
of agents was thought to possess a similar but more 
durable effect than metformin. Troglitazone was the 
first TZD approved by the United States’ Federal Drug 
Administration (FDA), and was soon accompanied by 
pioglitazone and rosiglitazone[79]. Trosiglitazone was 
removed from the market 4 years after its release, in 
2000. This was due to the FDA having received reports 
of 63 hepatic failure cases with lethal outcome in 
patients treated with troglitazone[80]. Two other TZDs, 
rosiglitazone and pioglitazone, have been linked to 
fluid retention, which limited their use in patients with 
congestive heart failure. Pioglitazone has been shown 
to have a potentially modest beneficial impact on CV 
disease but has also been associated with a possible 
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And finally, after the “ominous octet” was completed 
with the elucidation of overactivation or renal tubular 
glucose reabsorptive capacity[59­62] due to a markedly 
increased level of SGLT2 in the proximal renal tubular 
cells[86], the selective SGLT­2 inhibitors were developed. 
More precisely, when SGLT­2 is antagonized, the excess 
of glucose in the renal tubules is not reabsorbed but 
instead secreted in the urine. Canagliflozin was the first 
SGLT­2 inhibitor to be approved by the FDA, in March 
2013[87], which was followed by dapagliflozin in early 
2014 and finally by empagliflozin. 
Thus, here we described a wide spectrum of non­
insulin therapeutic agents currently used in type 2 
DM treatment. The official recommendations on their 
efficacy and safety, indications and contraindications, 
and effective combinations change almost on a yearly 
basis; yet, simultaneously we are experiencing an 
increase in diabetes­related complications, especially 
those leading to CV death[2,67]. This would, however, 
come as surprise if we kept in mind the results from 
the “Action to Control Cardiovascular Risk in Diabetes” 
trial[81] which clearly demonstrated that aggressive 
glycaemic control does not reduce the risk of CV death, 
despite the reduction in myocardial infarction.
NON-INSULIN THERAPEUTIC APPROACH 
AND CV RISK 
As aforementioned in detail, due to the complex 
pathophysiological background of type 2 DM with 
the wide spectrum of CV risk factors that coexist in 
addition to the hyperglycaemia itself. It is important 
to emphasize here that the promising effects in terms 
of CV risk reduction were first published back in the 
late 90’s, as an observation in the “STOP­NIDDM 
Trial” (an international study on the efficacy of an 
alpha­glucosidase inhibitor to prevent type 2 DM in a 
population with impaired glucose tolerance)[88]. The 
primary outcome of the study that clearly demonstrated 
that acarbose can prevent or delay the progression of 
impaired glucose tolerance to type 2 DM was recently 
confirmed in the “Acarbose Cardiovascular Evalua­
tion” (ACE) trial[89], but it showed no effect in CV risk 
reduction. Thus, the “Empagliflozin Cardiovascular 
Outcome Event Trial in type 2 DM Patients–Removing 
Excess Glucose” (EMPA­REG OUTCOME) was the first 
clinical study that demonstrated superiority of a glucose 
lowering agent, in CV disease, heart failure, and renal 
and mortality endpoints compared to placebo[90]. 
Given the glycated haemoglobin (HbA1c) reduction of 
0.45%, blood pressure in approximately 5/2 mmHg, 
and reduction in body weight by approximately 2%, the 
question arose: Could these results have been predicted 
based on what we knew about the mode of action? 
Thus, shortly after the EMPA­REG OUTCOME trial 
was published, Ferrannini et al[90] developed a so­
called “thrifty substrate” hypothesis which posits that 
in conditions of mild but persistent hyperketonaemia, 
β­hydroxybutyrate is taken up by the heart and oxidized 
into fatty acids. This selection of substrates improves 
the transduction process of oxygen consumption into 
work efficiency in the myocardiocytes. In addition, 
the enhanced oxygen release to the myocardium 
through haemoconcentration­driven by the diuresis[91,92] 
might affect a powerful synergy with the substrate 
shift. The rationale for this hypothesis came from 
experimental studies in diet­induced obese rats treated 
with dapagliflozin[93], ipragliflozin[94], or tofogliflozin[95] 
that demonstrated accelerated lipolysis and increased 
circulating ketone body levels, especially in the fasting 
state or when animals were fed in pairs. In addition, 
this was also confirmed in patients with type 2 DM 
following a 4­wk course of treatment with 25 mg of 
empagliflozin[96]. Concomitantly, both fasting and post­
meal plasma β­hydroxybutyrate concentrations were 
increased 2­fold to 3­fold and these changes were 
similar in time course, though attenuated in extent, in a 
group of non­diabetic volunteers receiving the drug. This 
hypothesis of the thrifty substrate might also explain the 
similar outcome obtained by the “Combined results from 
the Canagliflozin Cardiovascular Assessment Study” 
(CANVAS)[97]. Nevertheless, the post­market period has 
been too short to support any general conclusion at this 
time. 
And finally, some of the GLP-1 agonists, i.e., lirag­
lutde[98] and semaglutide[99] have shown a significant 
relative risk reduction compared with placebo for the 
3­point major adverse CV event primary outcome 
and relative risk in CV as well as in all­cause mortality, 
having low­to­moderate between­trial statistical hete­
rogeneity. However, the concerns about their potential 
in pancreatic cell proliferation observed in experimental 
studies has not been elucidated so far, due to the 
relatively short post­market period[100].
CONCLUSION
In this narrative review, we described the rapid deve­
lopment of the pathophysiology type 2 DM concept 
accompanied by lifesaving treatment options beyond 
insulin that have dramatically enhanced the quality 
of life and life expectancy of affected individuals. 
The nephroprotective effects of angiotensin­receptor 
blockade, angiotensin­converting enzyme inhibition and 
protein restriction have been shown[99­104], while laser 
photocoagulation has preserved the vision of millions 
of patients with diabetic retinopathy[105]. The target 
hyperglycaemic agents’ development has resulted 
in better glycaemic control, which has increased the 
focus of their potential in the context of development of 
diabetic complication preventive strategies. 
It is now known that better gluco­regulation resu­
lts in development and progression of microvascular 
complications, according to the large, population­
based studies of Diabetes Control and Complications 
Trial[106] as well as United Kingdom Prospective Diabetes 
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Study[107]. Additionally, the follow­up ACCORD study has 
showed reduced myocardial infarction with improved 
glycaemic control, but it didn’t provide an all­cause CV 
mortality rate. This finding raised awareness that an 
exclusively glucose­centric approach to diabetes will 
most likely not lead to reduction in all­cause CV disease 
mortality[98]. This finding was further strengthened by 
the Steno­2 trial[108,109], which demonstrated up to 50% 
CVD mortality with a multifactorial, instead of gluco­
centric, control.
Thus, the present position statement for type 2 
DM treatment comprises the simultaneous approach 
to control of glucose along with lipids, blood pressure 
and obesity[109,110]. Since obesity accompanies more 
than 80% of the type 2 DM population and contributes 
to other targeted factors’ improvement, its treatment 
strategy should be a priority in the comprehensive asse­
ssment of diabetes care. According to the American 
Diabetes Association Standards of Care from 2016, 
bariatric surgery should be considered in obesity 
management, in addition to behaviour modification and 
pharmacotherapy[111].
However, despite all the knowledge and all the 
pharmaceutic agents that are available, there will 
always be a need for more effective treatment op­
tions in order to affect the disease in an even more 
precise pathophysiological pathway, in the near 
future. For instance, we can expect a completely novel 
antidiabetic drug class­oxidative phosphorylation 
blockers, currently represented by imeglimin[112]. The 
underlying mechanism of action of this drug class 
consists of balancing bioenergetics in mitochondria 
and consequent insulin resistance to result in balance 
of insulin secretion and utilization as well as hepatic 
gluconeogenesis suppression. Thus, it is important to 
emphasize that this is not the sole promising novel drug 
class. This is indicated by findings from the research on 
the first­in­class drug, an adenosine monophosphate 
(AMP)­activated protein kinase activator, targeting one 
of the key players in the process of energy balance 
preservation, especially during caloric disturbances[113], 
and, finally, findings on the first monoclonal antibody, 
bimagrumab, that blocks the myostatin type Ⅱ receptor, 
which results in fat reduction[114].
In conclusion, given the raising burden of type 2 
DM and CV mortality due to diabetes, despite all of the 
therapeutic options that are available or will become 
available in due time, we should be focused on primary 
prevention, i.e., targeting preventive public health 
policies and in the rigorous evidence­based initiatives to 
introduce dietary products that will address metabolic 
disturbances. 
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